Skip to content
About Us
Technology
Pipelines
Team
News
中文
News
Categories
News
Multitude Therapeutics Announces Encouraging Interim Phase I Results from Ongoing First-in-Human Study Evaluating its CDH17-directed Antibody-Drug-Conjugate, AMT-676, in patients with advanced CRC at the 2026 ESMO GI Cancer Congress
2026-07-02
AMT-676 is a p…
Read More →
Phase I study of AMT-676, an anti-CDH17 antibody-drug conjugate, in patients with advanced CRC and other GI tumors
2026-07-02
Download Full …
Read More →
The Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) has granted Multitude Therapeutics’ AMT-253 Breakthrough Therapy Designation
2025-12-17
December 17, 2…
Read More →
Multitude Therapeutics Announces Encouraging Interim Phase I/II Results from Ongoing First-in-Human Study Evaluating its MUC18-directed Antibody-Drug-Conjugate, AMT-253, in Melanoma and Other Advanced Solid Tumors at the 2025 ESMO Annual Meeting
2025-10-19
Multitude Ther…
Read More →
Multitude Therapeutics Announces Promising Interim Phase I/II Results from the Ongoing First-in-Human Study Evaluating its CD44v9-directed Antibody-Drug-Conjugate, AMT-116, in Heavily Pretreated EGFR Wild-type Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors at the 2025 ESMO Annual Meeting
2025-10-17
Multitude Ther…
Read More →
